Compound Shows Promise as Next-Generation Prostate Cancer Therapy

Contact: Sarah Avery Phone: 919-660-1306 Email:sarah.avery@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) Monday, Aug. 8, 2016DURHAM, N.C. -- In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide.“Prostate cancer is the most prevalent form of cancer in men, and the principal driver of tumor growth is the androgen receptor,” saidJohn D. Norris, Ph.D., associate research professor in theDepartment of Pharmacology&Cancer Biology at Duke and senior author of a study published online Aug. 8 in the journal Nature Chemical Biology.“Suppression of androgen receptor function by anti-endocrine therapies is initially effective, but most tumors develop resistance, resulting in a more aggressive cancer,” Norris said. “Our research has been focused on finding a new approach to suppressing androgen receptor activity, because ev en in situations where tumors are resistant to current therapies, the androgen receptor remains a viable target.”Norris and colleagues focused on a group of CB compounds developed in collaboration with scientists at the Universi...
Source: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

Abstract Bone metastases can cause high morbidity and mortality, often developing as they advance, especially in patients with prostate and breast cancers. Most drugs are rarely distributed to the bone and are hence pharmacologically ineffective in treating bone metastases. The development of drug targeting technologies is required for the efficient treatment of bone metastases. To date, numerous bone-targeting ligands, including tetracyclines, bisphosphonates, aspartic acid, and aptamers have been developed and used for bone-targeted delivery of anti-tumor drugs, peptide/protein drugs, nucleic acid drugs, and dia...
Source: Chemical and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Chem Pharm Bull (Tokyo) Source Type: research
Using a deep-learning computer-aided diagnosis algorithm with multiparametric...Read more on AuntMinnie.comRelated Reading: Choline-PET boosts mpMRI for prostate cancer detection Prostate cancer patients prefer mpMRI over biopsy Ga-68 PSMA PET/MRI, mpMRI work for prostate cancer analysis
Source: Headlines - Category: Radiology Source Type: news
CONCLUSIONS Coexpression analysis of EZH2 identified its role in the cell cycle, mitosis, and DNA repair. The molecular mechanisms involved in EZH2 gene expression in the cell response to DNA damage requires further study to determine whether EZH2 is a potential human cancer biomarker. PMID: 32595202 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
athew Natural killer (NK) cells play a pivotal role in the immune system, especially in the recognition and clearance of cancer cells and infected cells. Their effector function is controlled by a delicate balance between the activating and inhibitory signals. We have identified 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) as NK cell receptors regulating NK cell cytotoxicity. Lectin-like transcript 1 (LLT1), a member of the C-type lectin-like domain family 2 (CLEC2D), induced IFN-g production but did not directly regulate cytolytic activity. Interestingly, LLT1 expressed on other cells acts as a ligand for an NK cell in...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract BACKGROUND: In accordance with the scientific literature heavy alcohol consumption (>50g per day) represents a risk factor for several diseases development, including cancer. However, the oncogenic role of light alcohol drinking (
Source: Reviews on Recent Clinical Trials - Category: Cancer & Oncology Authors: Tags: Rev Recent Clin Trials Source Type: research
Abstract Increased frequency of cancer in recent years and its impact on different physical, mental, and social dimensions of human life have turned it to a major problem of this century. We can group cancer according to the type of cells they start from viz. skin cancer, colon cancer, bladder cancer, breast cancer, prostate cancer, kidney cancer oral cancer etc. Among this, breast cancer is one of the most prevalent type of malignant neoplasm within women with more than one million new cases per year. In the recent years, with the help of targeted drug delivery system, several attempts were made to restrict the d...
Source: Current Diabetes Reviews - Category: Endocrinology Authors: Tags: Curr Diabetes Rev Source Type: research
AbstractIntroductionAntiprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations identified during clinical studies, further development was halted. Evaluation of antiprogestin pharmacology and pharmacokinetic data suggested that liver enzyme elevations might be related to off-target or metabolic effects ...
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
ConclusionsCancer management and death mostly occurred in SSH in France. Cancer patients frequently attend the emergency department and frequently receive chemotherapy during the last month of life. These data continue to contrast with those observed in Scandinavian- and English-speaking countries, in which management of the end of life at home is preferred.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Anticancer Activity of Novel NF-κB Inhibitor DHMEQ by Intraperitoneal Administration. Oncol Res. 2020 Jun 23;: Authors: Umezawa K, Breborowicz A, Gantsev S Abstract There have been great advances in the therapy of cancer and leukemia. But there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. Meanwhile, an NF-κB inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 2000. This compound was designed based on the structure of epoxyquinomicin isolated from a micro...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Genome-wide association studies (GWAS) have identified multiple independent cancer susceptibility loci at chromosome 8q24. We aimed to evaluate the associations between variants in the 8q24 region and cancer susceptibility. A comprehensive research synopsis and meta-analysis was performed to evaluate associations between 28 variants in 8q24 and risk of 7 cancers using data from 103 eligible articles totaling 146,932 cancer cases and 219,724 controls. Results: 20 variants were significantly associated with risk of prostate cancer, colorectal cancer, thyroid cancer, breast cancer, bladder cancer, stomach cancer, and glioma, ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Meta-Analysis of Observational Studies in Epidemiology Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Drugs & Pharmacology | Endocrine Therapy | Health | Legislation | National Institutes of Health (NIH) | Pediatrics | Politics | Prostate Cancer | Research | Study